Literature DB >> 10456769

Niaprazine in the treatment of autistic disorder.

P G Rossi1, A Posar, A Parmeggiani, E Pipitone, M D'Agata.   

Abstract

Niaprazine is a histamine H1-receptor antagonist with marked sedative properties. It has been employed in subjects with behavior and sleep disorders. No data concerning the use of niaprazine in subjects with autistic disorder are reported in the literature. The authors performed an open study to assess niaprazine efficacy in a sample of 25 subjects with autistic disorder and associated behavior and sleep disorders. Niaprazine was administered at 1 mg/kg/day for 60 days. A positive effect was found in 52% of patients, particularly on hyperkinesia, unstable attention, resistance to change and frustration, mild anxiety signs, heteroaggressiveness, and sleep disorders. Statistical comparison between responders and nonresponders showed no influence on niaprazine effect by age over or under 12 years, presence of neurologic signs, epilepsy, or abnormalities seen on brain imaging. Niaprazine was more efficacious in subjects with a mild or moderate degree of mental retardation. No side effects were observed. Because of its sedative effects and good tolerability, niaprazine can be used as a first-choice drug to improve behavior and sleep disorders in patients with autistic disorder.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10456769     DOI: 10.1177/088307389901400814

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  11 in total

Review 1.  The pathophysiology and treatment of autism.

Authors:  D J Posey; C J McDougle
Journal:  Curr Psychiatry Rep       Date:  2001-04       Impact factor: 5.285

2.  Optimization of a mathematical topological pattern for the prediction of antihistaminic activity.

Authors:  M J Duart; R García-Domenech; G M Antón-Fos; J Gálvez
Journal:  J Comput Aided Mol Des       Date:  2001-06       Impact factor: 3.686

Review 3.  Epidemiology and management of insomnia in children with autistic spectrum disorders.

Authors:  Silvia Miano; Raffaele Ferri
Journal:  Paediatr Drugs       Date:  2010-04-01       Impact factor: 3.022

Review 4.  Pharmacotherapy of pervasive developmental disorders in children and adolescents.

Authors:  Gabriele Masi
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  Effects of an H3R antagonist on the animal model of autism induced by prenatal exposure to valproic acid.

Authors:  Diego Baronio; Kamila Castro; Taylor Gonchoroski; Gabriela Mueller de Melo; Gustavo Della Flora Nunes; Victorio Bambini-Junior; Carmem Gottfried; Rudimar Riesgo
Journal:  PLoS One       Date:  2015-01-05       Impact factor: 3.240

6.  Histaminergic system in brain disorders: lessons from the translational approach and future perspectives.

Authors:  Diego Baronio; Taylor Gonchoroski; Kamila Castro; Geancarlo Zanatta; Carmem Gottfried; Rudimar Riesgo
Journal:  Ann Gen Psychiatry       Date:  2014-11-18       Impact factor: 3.455

Review 7.  Exploring the Validity of Valproic Acid Animal Model of Autism.

Authors:  Darine Froy N Mabunga; Edson Luck T Gonzales; Ji-Woon Kim; Ki Chan Kim; Chan Young Shin
Journal:  Exp Neurobiol       Date:  2015-12-16       Impact factor: 3.261

8.  Altered expression of histamine signaling genes in autism spectrum disorder.

Authors:  C Wright; J H Shin; A Rajpurohit; A Deep-Soboslay; L Collado-Torres; N J Brandon; T M Hyde; J E Kleinman; A E Jaffe; A J Cross; D R Weinberger
Journal:  Transl Psychiatry       Date:  2017-05-09       Impact factor: 6.222

Review 9.  Role of Neuroinflammation in Autism Spectrum Disorder and the Emergence of Brain Histaminergic System. Lessons Also for BPSD?

Authors:  Nermin Eissa; Adel Sadeq; Astrid Sasse; Bassem Sadek
Journal:  Front Pharmacol       Date:  2020-06-16       Impact factor: 5.810

10.  The Dual-Active Histamine H3 Receptor Antagonist and Acetylcholine Esterase Inhibitor E100 Alleviates Autistic-Like Behaviors and Oxidative Stress in Valproic Acid Induced Autism in Mice.

Authors:  Nermin Eissa; Sheikh Azimullah; Petrilla Jayaprakash; Richard L Jayaraj; David Reiner; Shreesh K Ojha; Rami Beiram; Holger Stark; Dorota Łażewska; Katarzyna Kieć-Kononowicz; Bassem Sadek
Journal:  Int J Mol Sci       Date:  2020-06-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.